These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22443466)

  • 1. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.
    Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG
    Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
    Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.
    Shord SS; Cuellar S
    J Am Pharm Assoc (2003); 2008; 48(4):487-93. PubMed ID: 18653424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
    Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
    Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
    Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
    Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
    Castelli R; Deliliers GL; Colombo R; Moreo G; Gallipoli P; Pantaleo G
    Ann Hematol; 2014 Sep; 93(9):1523-9. PubMed ID: 24711171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Bastit L; Vandebroek A; Altintas S; Gaede B; Pintér T; Suto TS; Mossman TW; Smith KE; Vansteenkiste JF
    J Clin Oncol; 2008 Apr; 26(10):1611-8. PubMed ID: 18375890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
    Ray-Coquard I; Laplaige P; Vey N; Asselain B; Urbieta M
    Curr Med Res Opin; 2010 Nov; 26(11):2653-60. PubMed ID: 20932223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
    González-Barón M; Ordóñez A; Franquesa R; Constenla M; Montalar J; Gili F; Camps C; Sancho JF; Pérez-Cachot P
    Cancer; 2002 Dec; 95(11):2408-13. PubMed ID: 12436449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Mustacchi G; Ceccherini R; Dellach C; Foladore S; Milani S; Leita M; Sisto M
    Ann Oncol; 2006 Nov; 17(11):1705-8. PubMed ID: 16980603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl.
    Hörl WH; Locatelli F; Haag-Weber M; Ode M; Roth K;
    Clin Nephrol; 2012 Jul; 78(1):24-32. PubMed ID: 22732334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
    Mark TL; McKenzie RS; Fastenau J; Piech CT
    Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
    Abraham I; Han L; Sun D; MacDonald K; Aapro M
    Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
    Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.